146 related articles for article (PubMed ID: 15506651)
1. Correlation between serum HER-2 oncoprotein and patients with breast cancer.
Yuan P; Xu BH; Chu DT
Chin Med Sci J; 2004 Sep; 19(3):212-5. PubMed ID: 15506651
[TBL] [Abstract][Full Text] [Related]
2. [Serum her-2/neu level and related factors in patients with breast cancer].
Yuan P; Xu BH; Zhang C; Qi J
Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
4. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
6. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV; Johansen JS; Price PA
Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
[TBL] [Abstract][Full Text] [Related]
7. Tissue expression and serum levels of HER-2/neu in patients with breast cancer.
Krainer M; Brodowicz T; Zeillinger R; Wiltschke C; Scholten C; Seifert M; Kubista E; Zielinski CC
Oncology; 1997; 54(6):475-81. PubMed ID: 9394844
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
[TBL] [Abstract][Full Text] [Related]
11. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.
Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A
J BUON; 2008; 13(3):409-13. PubMed ID: 18979558
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Chinchilli V; Engle L; Harvey HA; Brady C; Nalin CM; Dugan M; Carney W; Allard J
J Clin Oncol; 2002 Mar; 20(6):1467-72. PubMed ID: 11896093
[TBL] [Abstract][Full Text] [Related]
13. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
[TBL] [Abstract][Full Text] [Related]
14. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
15. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
16. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
[TBL] [Abstract][Full Text] [Related]
17. Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma.
Azam M; Qureshi A; Mansoor S
J Pak Med Assoc; 2009 Nov; 59(11):736-40. PubMed ID: 20361669
[TBL] [Abstract][Full Text] [Related]
18. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
19. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
[TBL] [Abstract][Full Text] [Related]
20. Serum IL-6 and IL-12 levels in breast cancer patients.
Hussein MZ; Al Fikky A; Abdel Bar I; Attia O
Egypt J Immunol; 2004; 11(2):165-70. PubMed ID: 16734129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]